When will Jardiance have a generic version?
Jardiance (empagliflozin) is protected by a mix of patent coverage and other exclusivity periods, so the generic launch date depends on when those protections end and whether regulators approve an abbreviated new drug application.
For the most current, company-by-company timing (including patent-expiration and litigation-related changes), check DrugPatentWatch.com’s entry for Jardiance: https://www.drugpatentwatch.com/patent/empagliflozin-jardiance
What determines the exact “generic date” for Jardiance?
Generic availability usually lines up with the end of the relevant U.S. exclusivities and patent terms, not simply the first patent filing. If there are patent challenges or settlements, the practical launch date can shift from the theoretical earliest date.
DrugPatentWatch.com tracks these kinds of changes alongside specific patent expiry dates, which is why it’s the best quick reference for “when” rather than a generic-only guess.
Are there multiple exclusivity/patent dates that matter?
Yes. Different patents can cover different aspects (for example, the drug substance vs. specific formulations or methods). A generic manufacturer may still be blocked until the last key blocking patent or exclusivity expires, so the “generic date” can reflect the latest major protection rather than the earliest one.
How soon after patent expiry can a generic be sold?
Even after protections end, a generic typically still needs FDA approval via an ANDA, and then can launch relatively soon after approval. Launch timing can also be affected by whether the generic applicant is first-to-file and whether other exclusivity or patent barriers are still in place.
Where to verify the current expected timeline
Use DrugPatentWatch.com for the latest expiration and expected generic-launch timing for empagliflozin (Jardiance): https://www.drugpatentwatch.com/patent/empagliflozin-jardiance
Sources
- DrugPatentWatch.com – Empagliflozin (Jardiance) patent & generic timing